Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Ciena | Dell Technologies | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Ciena's FY2025 10-K describes a technology position that has held but does not lock customers in. On the durable side, the strategy is to "build on and expand our global leadership in optical networking", resting on "our proprietary WaveLogic™ coherent modem technology" and approximately 2,400 issued patents with 800 more pending as of December 2, 2025. On the limiting side, the same filing says competition "remains intense" and features "aggressive selling efforts, including using significant pricing pressure to displace incumbent vendors", that "our customer contracts generally do not include minimum or guaranteed purchases", and that "there is no assurance that we will maintain our incumbency". Concentration cuts the same way: the five largest customers contributed approximately 50% of fiscal 2025 revenue, one cloud provider approximately 18%. Its income statement reports gross profit of $1,878.9M on $4,386.5M of revenue in FY2023, $1,719.6M on $4,015.0M in FY2024 and $2,004.9M on $4,769.5M in FY2025. Self-described leadership in its segments, with customers that are re-won deal by deal, is a narrow moat. | narrow The FY2026 10-K describes advantages that are real but shallow, and a revenue mix that is diluting them. It names them as 'our end-to-end solutions portfolio, go-to-market capabilities, supply chain, and global services' and calls the direct sales channel 'a significant competitive advantage', while conceding it faces 'ongoing product and price competition in all areas of our business from both branded and generic competitors' and, on components, that 'any disruption that may occur because of our dependence on single- or limited-source vendors would not disproportionately disadvantage us relative to our competitors' - i.e. no differentiated supply position. The filing's own margin table shows where the franchise actually earns: total gross margin fell from 23.8% of net revenue in Fiscal 2024 to 22.2% in Fiscal 2025 to 20.0% in Fiscal 2026, and inside that, product gross margin fell 17.5% to 15.8% to 13.7% while services gross margin rose 40.8% to 41.4% to 44.8%. Narrow rather than none, because the high-margin services and storage core is intact and its margin rate improved; narrow rather than wide, because the line that is growing carries a 13.7% product gross margin and the filing attributes the whole decline to it. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The FY2025 10-K locates the advantage in owned technology rather than in customer lock-in: "The success of our business and technology leadership depends significantly on our proprietary and internally developed technology." That technology is centred on WaveLogic, which Ciena's fiscal Q3 2026 earnings presentation (the source of the first two product rows below) defines as "Ciena's proprietary family of coherent optical chips — the core technology inside most of our networking products", and it reaches beyond Ciena's own systems: the 10-K's coherent pluggable transceivers use WaveLogic "for use within our systems and third-party equipment". Switching costs are the weaker candidate, because the same filing describes operators disaggregating line systems from modems and competitors using price to displace incumbents. | cost scale The filing locates the advantage in scale of distribution and supply, not in proprietary rights. It states 'Our world-class supply chain operates at significant scale', describes a direct sales force plus a partner network that produced 'approximately 40% of our net revenue' in Fiscal 2026, and lists supply chain and global services among its competitive advantages. The IP alternative is ruled out in the same document: with 25,859 granted patents held at January 30, 2026, Dell still says 'we are not substantially dependent on any single patent or group of related patents.' |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Slide 6 of Ciena's fiscal Q3 2026 earnings presentation of 2026-09-03 (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) lists "#1 in Data Center Interconnect Globally" (Dell'Oro Group), "#1 in Total Optical Networking in N. America" (Cignal AI, Dell'Oro Group, Omdia) and "#1 in Submarine Networks Globally" (Omdia), with market share measured as of Q2 2026 excluding China, and a caveat that Ciena "has not independently verified" the analyst data. On the company's own presentation of that data, that is the front rank in its core segments, but the presentation does not claim the global lead in total optical networking, and the FY2025 10-K says competition is "dominated by a small number of very large, multi-national companies" - Nokia, Huawei, Cisco, Hewlett Packard Enterprise and ZTE - many of which have "substantially greater financial, operational and marketing resources, and broader product offerings". A shared front rank, led by Ciena where the company-reported rankings measure it, rather than an uncontested one. | co leader The 10-K's only positioning claim is the unquantified 'Dell Technologies is a leader in the global technology industry'; it names no competitor and gives no share anywhere. The band therefore rests on disclosed absolute scale - ISG net revenue of 60,826m and CSG net revenue of 50,984m in Fiscal 2026, operations in over 170 countries - set against the filing's own admission that hyperscale Infrastructure-as-a-Service buyers 'often buy their infrastructure directly from original design manufacturers', which caps how much of the market Dell can lead at all. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Moderate, and improving. The FY2025 10-K's income statement reports gross profit of $1,878.9M on $4,386.5M, $1,719.6M on $4,015.0M and $2,004.9M on $4,769.5M of revenue for FY2023-FY2025, in a market where, the filing says, rivals use "significant pricing pressure to displace incumbent vendors" and "price and total cost of ownership" heads the list of competitive factors. Since then the AI build-out has lifted gross margin: Ciena's fiscal Q3 2026 earnings presentation (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) reports GAAP gross margin of 45.4% against 41.3% a year earlier, on revenue up 37% year over year, and guides fiscal 2027 adjusted gross margin to 45% to 46%. The presentation does not say how much of that is price rather than mix or volume, and the 10-K warns that AI-related demand has led to "a constrained supply environment" that can raise component costs. | weak The filing describes price-taking and its own tables confirm it. It reports 'ongoing product and price competition in all areas of our business from both branded and generic competitors' and says 'We closely monitor market pricing, including the effect of foreign exchange rate movements, in an effort to provide the best value for our customers.' Total gross margin fell from 23.8% of net revenue in Fiscal 2024 to 22.2% in Fiscal 2025 to 20.0% in Fiscal 2026, with product gross margin down to 13.7%; CSG operating margin fell three straight years (7.6%, 6.1%, 5.6% of segment revenue); and non-GAAP operating income as a percentage of net revenue 'decreased 10 basis points to 8.8%' even as revenue grew 19%. Consolidated operating margin did rise 70 basis points to 7.2%, but the filing credits a lower operating expense rate for that, not price. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Ciena is the optical-transport specialist among networking vendors - its fiscal Q3 2026 earnings presentation calls it "the only pure-play optical systems provider operating at scale today" - and its FY2025 10-K builds the business on one proprietary technology, the WaveLogic coherent modem, carried into the 6500 Packet-Optical Platform, Waveserver data center interconnect systems, the 6500 RLS photonic line system and coherent pluggable transceivers sold for Ciena's own systems and third-party equipment. Analyst rankings the company cites in that presentation, which it says it "has not independently verified", put Ciena first in data center interconnect globally, in total optical networking in North America and in submarine networks globally (Q2 2026, excluding China). The AI build-out has turned it into more of a cloud supplier than a telecom one: cloud providers were 53% of fiscal Q3 2026 revenue, revenue rose 37% year over year, and GAAP gross margin reached 45.4%. The 10-K is equally clear about why the position is narrow rather than wide. Competition is "dominated by a small number of very large, multi-national companies", many with greater resources; rivals use pricing to displace incumbents; contracts carry no minimum or guaranteed purchases; the five largest customers were about half of fiscal 2025 revenue; and disaggregation lets an operator buy the line system from one vendor and the modem from another, while the push into data-center interconnects brings Ciena up against Marvell, Credo and Broadcom. | The AI-server line is enormous and it is not a moat - the FY2026 10-K says so in its own margin bridge. AI-optimized servers net revenue went 1,873m in Fiscal 2024 to 9,286m in Fiscal 2025 to 24,683m in Fiscal 2026 (+396% then +166%), lifting total ISG revenue to 60,826m (+40%). Over the same year ISG operating income as a percentage of segment revenue fell 110 basis points to 11.7% 'due to a decline in gross margin rate that outpaced the decline in operating expense rate. Gross margin rate decreased primarily as the result of a shift in mix towards our AI-optimized servers offerings', and the Fiscal 2027 outlook repeats the expectation of 'margin rate pressure resulting from a continuing shift in mix towards our AI-optimized servers offerings'. The cleanest test of pass-through is the filing's product-versus-services split: product net revenue grew 27% to 90,405m at a 13.7% gross margin (down from 15.8% and 17.5%), while services net revenue fell 4% to 23,133m at a 44.8% gross margin. The AI boom arrived entirely as thin product revenue and did not pull the profitable services book along with it. What Dell adds is described plainly as integration: it uses contract manufacturers, buys components from suppliers and 'subsequently sell[s] those components to the manufacturer', and its own 'manufacturing process consists of assembly, software installation, functional testing, and quality control'. The bypass is named too: 'We also face competition from non-traditional IT companies, including large Infrastructure-as-a-Service providers, that often buy their infrastructure directly from original design manufacturers. Competitive pressures could increase if customers choose to move existing workloads to these providers.' What survives as a moat is the part an ODM cannot sell an enterprise: a direct sales force and account teams, a global service and support footprint whose gross margin rate is still rising, storage that held revenue within 3% of flat through the whole mix shift, and Dell Payment Solutions financing that produces multiyear recurring arrangements. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Ciena sits between optical-component suppliers and the operators building AI-era networks. Upstream, its FY2025 10-K says its products include "optical and electronic components for which reliable, high-volume supply is often available only from sole or limited sources", built by contract manufacturers with facilities in Canada, Mexico, Thailand, Vietnam and the United States; at November 1, 2025 it carried $826.2 million of inventory and $2.1 billion of purchase commitments. Downstream, the fiscal Q3 2026 earnings presentation puts direct cloud providers at 53% of the quarter's revenue against 37% for service providers, and describes its products as the links between data centers (data center interconnect) and between distributed AI training clusters ("scale-across"). | Integrator between accelerator and component suppliers and enterprise or sovereign buyers: the 10-K says Dell purchases components from suppliers, sells them on to contract manufacturers, and performs 'assembly, software installation, functional testing, and quality control', then reaches customers through a direct sales force and a partner network that generated about 40% of Fiscal 2026 net revenue. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |